Pharvaris N.V. (PHVS)
NASDAQ: PHVS · IEX Real-Time Price · USD
18.36
+0.29 (1.60%)
At close: Jul 19, 2024, 4:30 PM
18.41
+0.05 (0.27%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
Company Description
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases.
The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE).
It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Pharvaris N.V.
| Country | Netherlands |
| Founded | 2015 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 82 |
| CEO | Berndt Axel Edvard Modig CPA, M.B.A. |
Contact Details
Address: J.h. Oortweg 21, 2333 Ch Leiden Leiden, P7 00000 Netherlands | |
| Phone | 31 (0)71 203 6410 |
| Website | pharvaris.com |
Stock Details
| Ticker Symbol | PHVS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $20.00 |
| CIK Code | 0001830487 |
| CUSIP Number | N69605108 |
| ISIN Number | NL00150005Y4 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Berndt Axel Edvard Modig CPA, M.B.A. | Co-Founder, Chief Executive Officer and Executive Director |
| Anna Nijdam M.Sc., R.A. | Head of Strategic Finance and Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 28, 2024 | 6-K | Report of foreign issuer |
| Jun 12, 2024 | 144 | Filing |
| Jun 11, 2024 | 144 | Filing |
| Jun 11, 2024 | 6-K | Report of foreign issuer |
| Jun 10, 2024 | 144 | Filing |
| Jun 4, 2024 | 6-K | Report of foreign issuer |
| May 24, 2024 | 144 | Filing |
| May 22, 2024 | 144 | Filing |
| May 21, 2024 | 144 | Filing |
| May 8, 2024 | 6-K | Report of foreign issuer |